-$1.36 Earnings Per Share Expected for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) This Quarter

Equities research analysts expect that Arcutis Biotherapeutics, Inc. (NASDAQ:ARQTGet Rating) will post ($1.36) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Arcutis Biotherapeutics’ earnings, with estimates ranging from ($1.38) to ($1.34). Arcutis Biotherapeutics posted earnings per share of ($0.84) in the same quarter last year, which would suggest a negative year-over-year growth rate of 61.9%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Arcutis Biotherapeutics will report full year earnings of ($5.74) per share for the current fiscal year, with EPS estimates ranging from ($6.21) to ($5.49). For the next year, analysts expect that the firm will post earnings of ($4.08) per share, with EPS estimates ranging from ($5.08) to ($3.22). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Arcutis Biotherapeutics.

Arcutis Biotherapeutics (NASDAQ:ARQTGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($1.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.23.

ARQT has been the topic of several recent research reports. Mizuho reduced their price target on shares of Arcutis Biotherapeutics from $58.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, April 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcutis Biotherapeutics in a research note on Wednesday, February 23rd. Zacks Investment Research cut Arcutis Biotherapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 12th. The Goldman Sachs Group began coverage on Arcutis Biotherapeutics in a research report on Thursday, March 17th. They issued a “buy” rating and a $45.00 price objective on the stock. Finally, Morgan Stanley lifted their price objective on Arcutis Biotherapeutics from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Arcutis Biotherapeutics currently has a consensus rating of “Buy” and an average target price of $41.50.

NASDAQ ARQT traded up $0.53 during trading hours on Tuesday, reaching $18.78. The company’s stock had a trading volume of 2,111 shares, compared to its average volume of 253,259. The company has a debt-to-equity ratio of 0.24, a quick ratio of 12.09 and a current ratio of 12.09. The company’s 50-day moving average is $19.14 and its two-hundred day moving average is $18.21. Arcutis Biotherapeutics has a fifty-two week low of $13.59 and a fifty-two week high of $29.37. The stock has a market cap of $965.67 million, a PE ratio of -4.04 and a beta of 0.28.

In other news, CEO Todd Franklin Watanabe sold 2,489 shares of the business’s stock in a transaction on Friday, March 4th. The shares were sold at an average price of $16.86, for a total transaction of $41,964.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Howard G. Welgus sold 7,500 shares of the company’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $20.02, for a total value of $150,150.00. The disclosure for this sale can be found here. Insiders sold a total of 553,267 shares of company stock valued at $11,424,366 over the last quarter. 39.00% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in ARQT. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Arcutis Biotherapeutics during the 1st quarter worth approximately $29,000. Royal Bank of Canada lifted its position in shares of Arcutis Biotherapeutics by 59.8% during the second quarter. Royal Bank of Canada now owns 2,053 shares of the company’s stock worth $56,000 after purchasing an additional 768 shares in the last quarter. Denali Advisors LLC acquired a new stake in Arcutis Biotherapeutics during the 4th quarter valued at $77,000. Thrivent Financial for Lutherans purchased a new stake in Arcutis Biotherapeutics during the 3rd quarter worth $248,000. Finally, Guggenheim Capital LLC acquired a new position in Arcutis Biotherapeutics in the 4th quarter worth $222,000. 87.59% of the stock is currently owned by hedge funds and other institutional investors.

About Arcutis Biotherapeutics (Get Rating)

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

Recommended Stories

Get a free copy of the Zacks research report on Arcutis Biotherapeutics (ARQT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arcutis Biotherapeutics (NASDAQ:ARQT)

Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.